% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Neu:303420,
      author       = {M. A. Neu and E. Dreismickenbecker and F. Lanfranconi and
                      S. Stössel and A. Balduzzi and P. Wright and S. Windsor and
                      J. Wiskemann$^*$ and I. El-Rajab$^*$ and A. Lucia and C.
                      Fiuza-Luces and R. Mongondry and M. K. Fridh and F.
                      Spreafico and B. Konda and L. Kitanovski and B. Heißerer
                      and M. Polak and T. Baader and W. Bloch and M. Götte and K.
                      Rizvi and C. Ruckes and N. W. Paul and J. Faber},
      collaboration = {N. ActiveOncoKids and Y. C. Europe and F. Consortium},
      othercontributors = {A. Schwalber and O. Pérol and H. B. Larsen and T. P.
                          Moriggi and W. Zardo and A. Bertrand and L. Wypyrsczyk and
                          M. Kühn and A. Robinson and H. Diel},
      title        = {{G}et strong to fight childhood cancer - an exercise
                      intervention for children and adolescents undergoing
                      anti-cancer treatment ({FORTE}e): {R}ationale and design of
                      a randomized controlled exercise trial.},
      journal      = {BMC cancer},
      volume       = {25},
      number       = {1},
      issn         = {1471-2407},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2025-01645},
      pages        = {1275},
      year         = {2025},
      note         = {Wiskemann D120 ?},
      abstract     = {Despite substantial advances in treatment, children and
                      adolescents with cancer continue to face high morbidity and
                      health issues, including cancer-related fatigue,
                      treatment-related complications, and physical inactivity.
                      Integrating exercise into pediatric oncology care has
                      emerged as a promising approach to mitigate these burdens
                      during cancer treatment. While preliminary data support its
                      potential to reduce treatment-related side effects and
                      enhance quality of life, robust evidence -especially from
                      large, multicenter trials- remains limited.The FORTEe trial
                      is a randomized, controlled, multicenter trial evaluating a
                      personalized and standardized exercise intervention powered
                      to include 450 children, adolescents, and young adults
                      undergoing cancer treatment across ten centers in Europe.
                      The trial aims to provide high-quality evidence for
                      integrating precision exercise therapy as part of standard
                      care. Participants are randomly assigned to either the
                      exercise intervention group, receiving a tailored,
                      supervised 8-10 weeks lasting exercise program, or the
                      control group, receiving usual care. The exercise program
                      includes endurance, strength, flexibility, and balance
                      training, adapted to each patient's age, fitness, and cancer
                      treatment phase. Exercise sessions are intended to take
                      place 3-5 times a week with moderate intensity, with both
                      frequency and intensity adapted to the clinical condition of
                      the individual. Digital tools and telehealth solutions
                      support the intervention, allowing for both in-person and
                      remote training.With a target enrolment of 450 patients, the
                      FORTEe trial will be one of the largest interventional
                      studies in pediatric exercise oncology. Given that childhood
                      cancer is a rare disease, this sample size is only
                      achievable through a multicenter approach. Enhancing
                      statistical power, the large sample will enable more robust
                      analyses of the intervention's effects in a diverse
                      population across multiple European centers.As a progress
                      beyond the current state-of-the-art, FORTEe has the ambition
                      to implement pediatric exercise oncology as an
                      evidence-based treatment option for all childhood cancer
                      patients, ultimately integrating it as a standard into
                      clinical practice worldwide.The FORTEe trial was
                      prospectively registered in the German Clinical Trials
                      Register (DRKS00027978) on 28 January 2022 and on
                      ClinicalTrials.gov (NCT05289739) on 21 March 2022.},
      keywords     = {Humans / Adolescent / Child / Neoplasms: therapy / Exercise
                      Therapy: methods / Quality of Life / Randomized Controlled
                      Trials as Topic / Male / Female / Young Adult / Multicenter
                      Studies as Topic / Cancer-related fatigue (Other) /
                      Childhood cancer (Other) / Exercise intervention (Other) /
                      Pediatric Oncology (Other) / Physical activity (Other) /
                      Randomized controlled trial (Other) / Supportive Care
                      (Other) / Training (Other)},
      cin          = {D120},
      ddc          = {610},
      cid          = {I:(DE-He78)D120-20160331},
      pnm          = {314 - Immunologie und Krebs (POF4-314)},
      pid          = {G:(DE-HGF)POF4-314},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40775303},
      doi          = {10.1186/s12885-025-14489-y},
      url          = {https://inrepo02.dkfz.de/record/303420},
}